4 studies found for:    DCDS4501A
Show Display Options
Rank Status Study
1 Completed A Study of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and DCDS4501A in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma
Condition: Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Interventions: Drug: DCDS4501A;   Drug: rituximab
2 Recruiting A Safety and Efficacy Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab (MabThera/Rituxan) or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab and Polatuzumab Vedotin Combined With Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (ROMULUS)
Condition: Diffuse Large B-Cell Lymphoma, Lymphoma, Follicular
Interventions: Drug: Obinutuzumab;   Drug: Pinatuzumab Vedotin;   Drug: Polatuzumab Vedotin;   Drug: Rituximab
3 Recruiting A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Bendamustine;   Drug: Obinutuzumab;   Drug: Polatuzumab vedotin;   Drug: Rituximab
4 Recruiting A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non Hodgkin
Interventions: Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Obinutuzumab;   Drug: Polatuzumab Vedotin;   Drug: Prednisolone;   Drug: Prednisone;   Drug: Rituximab

Study has passed its completion date and status has not been verified in more than two years.